Applicability, safety, and biological activity of regulatory T cell therapy in liver transplantation
Year: 2019
Type: article
Study design: Clinical Trial
Abstract: Regulatory T cells (Tregs) are a lymphocyte subset with intrinsic immunosuppressive properties that can be expanded in large numbers ex vivo and have been shown to prevent allograft rejection and promote tolerance in animal models. To investigate the safety, applicability, and biological activity of autologous Treg adoptive transfer in humans, we conducted an open-label, dose-escalation, Phase I clinical trial in liver transplantation. Patients were enrolled while awaiting liver transplantation or 6-12 months posttransplant. Circulating Tregs were isolated from blood or leukapheresis, expanded under good manufacturing practices (GMP) conditions, and administered intravenously at either 0.5-1 million Tregs/kg or 3-4.5 million Tregs/kg. The primary endpoint was the rate of dose- limiting toxicities occurring within 4 weeks of infusion. The applicability of the clinical protocol was poor unless patient recruitment was deferred until 6-12 months posttransplant. Thus, only 3 of the 17 patients who consented while awaiting liver transplantation were dosed. In contrast, all six patients who consented 6-12 months posttransplant received the cell infusion. Treg transfer was safe, transiently increased the pool of circulating Tregs and reduced anti-donor T cell responses. Our study opens the door to employing Treg immunotherapy to facilitate the reduction or complete discontinuation of immunosuppression following liver transplantation.
DOI: 10.1111/ajt.15700
Authors: Alberto Sánchez-Fueyo, Gavin Whitehouse, Nathali Grageda, Matthew E. Cramp, Tiong Y. Lim, Marco Romano, Sarah Thirkell, Katie Lowe, Laura Fry, Julie Heward, Alex Kerr, Jakia Ali, Chris Fisher, Gillian Lewis, Andrew Hope, Elisavet Kodela, Mike Lyne, Farzin Farzaneh, Shahram Kordasti, Irene Rebollo-Mesa, Juan Jose Lozano, Niloufar Safinia, Nigel Heaton, Robert Lechler, Marc Martínez-Llordella, Giovanna Lombardi
Language: English
Topic: T-cell and B-cell Immunology
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,300
Funders: NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research, Cancer Research UK, National Institute for Health and Care Research, British Heart Foundation, King's College London, Medical Research Council, Biotechnology and Biological Sciences Research Council
Awards: USE OF LOW-DOSE IL-2 TO EXPAND ENDOGENOUS REGULATORY T CELLS AND ACHIEVE TRANSPLANTATION TOLERANCE, G1908936996, Large scale lentiviral vector production, Optimising the efficacy of regulatory T cells: informing clinical application (renewal), G357864157, ThRIL;A 'first-in-human' study, evaluating the safety, tolerability with an investigation into the efficacy of Tregs in liver transplant recipients, G4119076191, G4124537697, G4388919642, BRIC: Packaging cell lines for inherently manufacturable viral vectors, SPONTANEOUSLY BIOTINYLATED LENTIVIRAL VECTORS FOR ENVELOPE INDEPENDENT TARGETING OF INFECTION
OpenAlex ID: W2983615744
